Michael Hund is the CEO of EB Research Partnership (EBRP), a trailblazing medical research organization focused on curing Epidermolysis Bullosa (EB), a life-threatening genetic skin disease. Under his leadership EBRP has accelerated the landscape from 2 to over 40 clinical trials and via their award winning venture philanthropy methodology funded the first FDA approved treatment for EB in 2023, the first ever topical gene therapy. In Michael’s tenure, EBRP’s innovative business model has garnered recognition from Harvard Business School, Yale University, MIT, Stanford Social Innovation Review, Rolling Stone, and Forbes. With a background at the Multiple Myeloma Research Foundation and Paul Newman’s Hole in the Wall Gang Fund, he has dedicated his career to transforming healthcare.
Michael received his Master’s in Business Administration (MBA) from Yale University, CORe credential from Harvard Business School, and an undergraduate degree in Philosophy from the University of Kansas. He is the recipient of the MIT Solve Horizon Innovation Award, Social Innovations Journal Leadership Award, Top 100 Magazine Innovators, and Authority Magazine’s Social Innovators. He lives in Connecticut with his wife Sarah and four daughters.
COMPANY WEBSITE: https://www.ebresearch.org/
CEO LINKEDIN: https://www.linkedin.com/in/michaelhund/
COMPANY FACEBOOK PAGE: https://www.facebook.com/EBResearch/
COMPANY TWITTER PAGE: https://twitter.com/ebresearch
COMPANY INTSTAGRAM: https://www.instagram.com/ebresearch/
COMPANY LINKEDIN: https://www.linkedin.com/company/eb-research-partnership/